...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Thoracic Disease >Comparing the benefits of postoperative adjuvant chemotherapy vs . observation for stage IB non-small cell lung cancer: a meta-analysis
【24h】

Comparing the benefits of postoperative adjuvant chemotherapy vs . observation for stage IB non-small cell lung cancer: a meta-analysis

机译：术后辅助化疗与化疗的比较。 IB期非小细胞肺癌的临床观察：一项荟萃分析

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The aim of this meta-analysis was to compare the benefits of postoperative adjuvant chemotherapy vs. observation for stage IB non-small cell lung cancer (NSCLC). Methods: A literature search was performed in PubMed, Embase, and Cochrane Library databases, and stage IB NSCLC patients were assigned to the postoperative adjuvant chemotherapy and observation groups. The 5-year overall survival (OS), 5-year disease-free survival (DFS), local recurrence, and distant metastasis were then assessed. In addition, statistical analysis was conducted using Review Manager 5.3 software. Results: The meta-analysis involved nine articles and included 1,645 stage IB patients. There was no significance in the 5-year OS [relative risk (RR) =1.05; 95% confidence interval (CI): 0.98–1.13; P=0.14] and 5-year DFS (RR =1.29; 95% CI: 0.97–1.72; P=0.08) between the postoperative adjuvant chemotherapy and observation groups. However, there was a significant difference in local recurrence (RR =0.43; 95% CI: 0.23–0.80; P=0.007) and distant metastasis (RR =0.68; 95% CI: 0.48–0.97; P=0.03) between the two groups. Conclusions: Adjuvant chemotherapy might not be recommended for stage IB NSCLC.
机译：背景：本荟萃分析的目的是比较术后辅助化疗与IB期非小细胞肺癌（NSCLC）观察的益处。方法：在PubMed，Embase和Cochrane Library数据库中进行文献检索，并将IB期NSCLC患者分为术后辅助化疗和观察组。然后评估了5年总生存期（OS），5年无病生存期（DFS），局部复发和远处转移。此外，使用Review Manager 5.3软件进行了统计分析。结果：荟萃分析涉及9篇文章，包括1,645名IB期患者。 5年OS无统计学意义[相对风险（RR）= 1.05; 95％置信区间（CI）：0.98–1.13; P = 0.14]和术后辅助化疗与观察组之间的5年DFS（RR = 1.29; 95％CI：0.97-1.72; P = 0.08）。然而，两者之间的局部复发率（RR = 0.43; 95％CI：0.23–0.80; P = 0.007）和远处转移（RR = 0.68; 95％CI：0.48–0.97; P = 0.03）存在显着差异。组。结论：IB期NSCLC可能不推荐辅助化疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号